SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Pacira BioSciences, Inc. (PCRX) trades at a trailing P/E of 142.0, forward P/E of 9.0. Trailing earnings yield is 0.70%, forward earnings yield 11.11%. PEG 0.01 (Peter Lynch undervalued ≤1.0). Graham Number is $7.79.
Criteria proven by this page:
- VALUE (27/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 142.0); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY 0.70%).
- Forward P/E 9.0 (down from trailing 142.0) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.01 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 0.70% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 11.11% as earnings recover.
- Analyst consensus target $27.00 (+13.7% upside) — modest upside expected.
Overall SharesGrow Score: 45/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
27/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — PCRX
Valuation Multiples
P/E (TTM)142.0
Forward P/E9.0
PEG Ratio0.01
Forward PEG0.01
P/B Ratio1.44
P/S Ratio1.39
EV/EBITDA10.7
Per Share Data
EPS (TTM)$0.17
Forward EPS (Est.)$2.64
Book Value / Share$16.31
Revenue / Share$17.10
FCF / Share$3.22
Yields & Fair Value
Earnings Yield0.70%
Forward Earnings Yield11.11%
Dividend Yield0.00%
Graham Number$7.79
SharesGrow IV$12.11 (-49%)
Analyst Target$27.00 (+13.7%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
-31.7 |
0.01 |
5.49 |
4.35 |
- |
| 2017 |
-42.6 |
-8.70 |
6.50 |
6.34 |
- |
| 2018 |
-3,736.7 |
37.77 |
5.48 |
5.22 |
- |
| 2019 |
-170.7 |
-0.08 |
5.30 |
4.47 |
- |
| 2020 |
17.5 |
-0.01 |
4.12 |
5.94 |
- |
| 2021 |
63.4 |
-0.88 |
3.65 |
4.92 |
- |
| 2022 |
110.5 |
-1.75 |
2.27 |
2.64 |
- |
| 2023 |
37.2 |
0.23 |
1.79 |
2.31 |
- |
| 2024 |
-8.8 |
0.03 |
1.12 |
1.24 |
- |
| 2025 |
164.0 |
-1.53 |
1.66 |
1.59 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-1.02 |
$276.37M |
$-37.95M |
-13.7% |
| 2017 |
$-1.07 |
$286.63M |
$-42.61M |
-14.9% |
| 2018 |
$-0.01 |
$337.28M |
$-471K |
-0.1% |
| 2019 |
$-0.27 |
$421.03M |
$-11.02M |
-2.6% |
| 2020 |
$3.33 |
$420.83M |
$145.52M |
34.6% |
| 2021 |
$0.92 |
$541.53M |
$41.98M |
7.8% |
| 2022 |
$0.34 |
$666.82M |
$15.91M |
2.4% |
| 2023 |
$0.81 |
$674.98M |
$41.96M |
6.2% |
| 2024 |
$-2.15 |
$700.97M |
$-99.56M |
-14.2% |
| 2025 |
$0.16 |
$726.41M |
$7.03M |
1% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$2.65 |
$2.30 – $2.97 |
$761.73M |
$761.33M – $762.13M |
4 |
| 2027 |
$3.49 |
$2.61 – $3.93 |
$830.51M |
$823.4M – $844.47M |
4 |
| 2028 |
$4.77 |
$4.70 – $4.88 |
$960.98M |
$954.22M – $967.74M |
3 |
| 2029 |
$4.60 |
$4.53 – $4.71 |
$924.91M |
$913.57M – $941.38M |
2 |
| 2030 |
$4.95 |
$4.87 – $5.06 |
$935.3M |
$923.84M – $951.96M |
2 |
